|Emtora Biosciences, of San Antonio||eRapa (submicron rapamycin)||mTOR inhibitor||Prostate cancer||In poster describing phase Ib findings in 14 participants with low-grade disease, low-dose eRapa was safe and well-tolerated; dose of 0.5 mg daily produced predictable, low and stable blood concentration levels and enhanced CD8+ memory T cells|
|Genprex Inc., of Austin, Texas||Oncoprex||Immunogene therapy||Non-small-cell lung cancer||Won't reopen enrollment of patients in study testing the drug in combination with Tarceva (erlotinib, Roche Holding AG); plans to start a phase I/II study testing the drug in combination with Tagrisso (osimertinib, Astrazeneca plc) in mid-2020|
|Phasebio Pharmaceuticals Inc., of Malvern, Pa.||PB-1046||VIP 2 receptor agonist||Pulmonary arterial hypertension||Data from single participant who was dosed for > 18 months in phase Ib/IIa pilot study based on continued improvements in hemodynamic parameters showed reductions in mean pulmonary artery pressure and total pulmonary resistance and increases in stroke volume and cardiac output without increase in heart rate, which were sustained up to 3 months after final dose|
|Aivita Biomedical Inc., of Irvine, Calif.||AV-GBM-1||Autologous-tumor-associated-antigen-transfected autologous dendritic cell vaccine||Glioblastoma||Enrollment target of about 55 participants achieved ahead of schedule and under budget, with 94% treatment manufacturing success rate|
|Menlo Therapeutics Inc., of Redwood City, Calif.||Serlopitant||NK1 receptor antagonist||Pruritus||Findings that trial to treat pruritus in individuals with psoriasis met its primary endpoint, showing statistically significant reduction vs. placebo at week 8, published in Journal of the American Academy of Dermatology|
|Abbvie Inc., of North Chicago||Rinvoq (upadacitinib)||JAK inhibitor||Psoriatic arthritis||Dosed at 15 mg and 30 mg once daily, drug met primary endpoint of ACR20 response at week 12 (71% and 79%, respectively) vs. placebo (36%) in adults with active disease (p<0.0001); 30-mg dose achieved superiority to adalimumab in ACR20 response at week 12 and both doses achieved noninferiority vs. adalimumab; both doses inhibited radiographic progression at week 24 compared to placebo (p<0.01)|
|Minerva Neurosciences Inc., of Waltham, Mass.||Roluperidone||5-HT 2a receptor antagonist; opioid receptor sigma antagonist 2||Schizophrenia||Enrollment completed in pivotal trial assessing effect on negative symptoms in schizophrenia, with 515 participants randomized; top-line data expected in second quarter of 2020|
For more information about individual companies and/or products, see Cortellis.